74 related articles for article (PubMed ID: 10216510)
21. High-dose chemotherapy (CTM) for breast cancer.
Damon LE; Wolf JL; Rugo HS; Gold E; Zander AR; Cassidy M; Cecchi G; Cohen N; Irwin D; Tracy M; Ries CA; Linker CA
Bone Marrow Transplant; 2000 Aug; 26(3):257-68. PubMed ID: 10967563
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy with autologous stem cell rescue in stage IIIB inflammatory breast cancer.
Yalamanchili K; Lalmuanpuii J; Waheed F; Farjami S; Kancherla R; Qureshi Z; Hoang A; Khaled Y; Lake D; Puccio C; Chun HG; Seiter K; Ahmed T
Anticancer Res; 2008; 28(5B):3139-42. PubMed ID: 19031971
[TBL] [Abstract][Full Text] [Related]
23. The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo.
Hassan Z; Hellström-Lindberg E; Alsadi S; Edgren M; Hägglund H; Hassan M
Bone Marrow Transplant; 2002 Aug; 30(3):141-7. PubMed ID: 12189531
[TBL] [Abstract][Full Text] [Related]
24. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
[TBL] [Abstract][Full Text] [Related]
25. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
[TBL] [Abstract][Full Text] [Related]
26. High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome.
Ahmed T; Kancherla R; Qureshi Z; Mittelman A; Seiter K; Mannancheril A; Puccio C; Chun HG; Bar M; Lipshutz M; Ali MF; Goldberg R; Preti R; Lake D; Durrani H; Farley T
Bone Marrow Transplant; 2000 May; 25(10):1041-5. PubMed ID: 10828863
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic recovery of ex vivo perfusion culture expanded bone marrow and unexpanded peripheral blood progenitors after myeloablative chemotherapy.
Engelhardt M; Douville J; Behringer D; Jähne A; Smith A; Henschler R; Lange W
Bone Marrow Transplant; 2001 Feb; 27(3):249-59. PubMed ID: 11277172
[TBL] [Abstract][Full Text] [Related]
28. Limits of stimulation of proliferation and differentiation of bone marrow cells of mice treated with swainsonine.
Oredipe OA; Furbert-Harris PM; Laniyan I; Griffin WM; Sridhar R
Int Immunopharmacol; 2003 Oct; 3(10-11):1537-47. PubMed ID: 12946451
[TBL] [Abstract][Full Text] [Related]
29. CD97 is differentially expressed on murine hematopoietic stem-and progenitor-cells.
van Pel M; Hagoort H; Hamann J; Fibbe WE
Haematologica; 2008 Aug; 93(8):1137-44. PubMed ID: 18603564
[TBL] [Abstract][Full Text] [Related]
30. Mitoxantrone: bluebeard for malignancies.
van der Graaf WT; de Vries EG
Anticancer Drugs; 1990 Dec; 1(2):109-25. PubMed ID: 2151849
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD
Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
[TBL] [Abstract][Full Text] [Related]
34. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
35. Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone.
Carlo-Stella C; Di Nicola M; Milani R; Longoni P; Milanesi M; Bifulco C; Stucchi C; Guidetti A; Cleris L; Formelli F; Garotta G; Gianni AM
Exp Hematol; 2004 Feb; 32(2):171-8. PubMed ID: 15102478
[TBL] [Abstract][Full Text] [Related]
36. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
[TBL] [Abstract][Full Text] [Related]
37. High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule.
Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Esposito M; Vannozzi MO; Sorice G; Friedman D; Puglisi M; Brema F; Mela GS; Sessarego M; Patrone F
Br J Cancer; 1997; 76(6):797-804. PubMed ID: 9310249
[TBL] [Abstract][Full Text] [Related]
38. Mitoxantrone salvage in heavily pretreated advanced breast cancer.
Nathanson L; Williams ME
Prog Clin Biol Res; 1987; 248():283-7. PubMed ID: 3671416
[No Abstract] [Full Text] [Related]
39. Mitoxantrone: potential for use in intensive therapy.
LeMaistre CF; Herzig R
Semin Oncol; 1990 Feb; 17(1 Suppl 3):43-8. PubMed ID: 2406923
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of mitoxantrone for liver metastases from breast cancer.
O'Reilly SM; Coleman RE; Rubens RD
Cancer Chemother Pharmacol; 1989; 25(1):73-4. PubMed ID: 2591004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
